Blockade of immune checkpoints, such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) (2, 3), has made a great contribution in the immunotherapy of various cancers in recent years. This evidence concerns the gene CTLA4 and cancer.